VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vaxart, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026
- Market cap
- $115.15M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 243M shares
Institutional holders
4
1 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
5 buys · 0 sales
Net bought $30.64K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | 15,384,615 | 9.10% | 13G (passive) | Jan 18, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VXRT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Heritage Wealth Advisors | 29,655 | 0.01% | $17.94K | – | 0.00% |
| Lvm Capital Management Ltd/Mi | 25,000 | 0.01% | $15 | – | 0.00% |
| Kingswood Wealth Advisors, LLC | 10,005 | 0.00% | $6.05K | New | 0.00% |
| Archer Investment Corp | 30 | 0.00% | $18 | +15 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4 | 0M | 0.0% | 1 / 1 | 0 / 2 | 0M | 0M |
| Q1 2026 | 5 | 0M | 0.0% | 2 / 1 | 0 / 1 | 0M | 0M |
| Q4 2025 | 5 | 0M | 0.0% | 1 / 1 | 0 / 13 | 0M | 2M |
| Q3 2025 | 17 | 2M | 1.0% | 3 / 5 | 1 / 84 | 0M | 21M |
| Q2 2025 | 98 | 23M | 9.5% | 17 / 20 | 18 / 10 | 4M | 8M |
| Q1 2025 | 92 | 27M | 11.2% | 12 / 15 | 24 / 12 | 1M | 10M |
| Q4 2024 | 93 | 36M | 14.7% | 13 / 23 | 24 / 18 | 2M | 4M |
| Q3 2024 | 100 | 38M | 15.5% | 18 / 15 | 26 / 17 | 4M | 5M |
| Q2 2024 | 100 | 41M | 16.7% | 22 / 21 | 22 / 24 | 22M | 22M |
| Q1 2024 | 104 | 41M | 16.9% | 29 / 27 | 19 / 11 | 26M | 1M |
| Q4 2023 | 87 | 17M | 6.9% | 7 / 24 | 20 / 16 | 2M | 4M |
| Q3 2023 | 96 | 18M | 7.6% | 8 / 19 | 30 / 23 | 1M | 11M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven Lo | President, Chief Exec Officer, Director | 2,585,606 | 1.06% | Mar 26, 2026 |
| Jeroen Nicolaas Grasman | Chief Financial Officer | 545,605 | 0.22% | May 21, 2026 |
| Sean Tucker | SVP, Chief Scientific Officer | 943,336 | 0.39% | Mar 31, 2026 |
| James F. Cummings | Chief Medical Officer | 924,177 | 0.38% | Mar 31, 2026 |
| Edward B. Berg | SVP, General Counsel | 755,368 | 0.31% | Mar 26, 2026 |
| Phillip E. Lee | Chief Financial Officer | 631,619 | 0.26% | Mar 26, 2025 |
| Kevin Finney | Director | 244,171 | 0.10% | Jul 20, 2026 |
| James B. Breitmeyer | Director | 87,115 | 0.04% | Jul 17, 2026 |
| David E. Wheadon | Director | 86,150 | 0.04% | Jul 17, 2026 |
| Elaine J. Heron | Director | 135,966 | 0.06% | Jul 17, 2026 |
| W. Mark Watson | Director | 173,525 | 0.07% | Jul 17, 2026 |
| Michael J. Finney | Director | 702,840 | 0.29% | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kevin Finney Director | Jul 16, 2026 | Award | +39,400 | – | – | 244,171 |
| W. Mark Watson Director | Jul 16, 2026 | Award | +39,400 | – | – | 173,525 |
| James B. Breitmeyer Director | Jul 16, 2026 | Award | +8,315 | – | – | 87,115 |
| David E. Wheadon Director | Jul 16, 2026 | Award | +39,400 | – | – | 86,150 |
| Elaine J. Heron Director | Jul 16, 2026 | Award | +39,400 | – | – | 135,966 |
| W. Mark Watson Director | May 22, 2026 | Buy | +10,000 | $0.65 | $6.50K | 134,125 |
| Jeroen Nicolaas Grasman Chief Financial Officer | May 19, 2026 | Tax withholding | −31,395 | $0.61 | $19.15K | 545,605 |
| James B. Breitmeyer Director | Apr 23, 2026 | Award | +78,800 | – | – | 78,800 |
| James F. Cummings Chief Medical Officer | Mar 28, 2026 | Tax withholding | −3,292 | $0.65 | $2.14K | 924,177 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 28, 2026 | Tax withholding | −3,924 | $0.65 | $2.55K | 882,811 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 24, 2026 | Tax withholding | −36,418 | $0.69 | $25.13K | 886,735 |
| Steven Lo President, Chief Exec Officer, Director | Mar 24, 2026 | Tax withholding | −126,028 | $0.69 | $86.96K | 2,485,606 |
| James F. Cummings Chief Medical Officer | Mar 24, 2026 | Tax withholding | −30,551 | $0.69 | $21.08K | 927,469 |
| Edward B. Berg SVP, General Counsel | Mar 24, 2026 | Tax withholding | −36,418 | $0.69 | $25.13K | 755,368 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 18, 2026 | Tax withholding | −8,072 | $0.63 | $5.09K | 923,153 |
| James F. Cummings Chief Medical Officer | Mar 18, 2026 | Tax withholding | −6,772 | $0.63 | $4.27K | 958,020 |
| Edward B. Berg SVP, General Counsel | Mar 18, 2026 | Tax withholding | −8,072 | $0.63 | $5.09K | 791,786 |
| Steven Lo President, Chief Exec Officer, Director | Mar 18, 2026 | Tax withholding | −22,425 | $0.63 | $14.13K | 2,611,634 |
| James F. Cummings Chief Medical Officer | Mar 16, 2026 | Award | +227,000 | – | – | 964,792 |
| Jeroen Nicolaas Grasman Chief Financial Officer | Mar 16, 2026 | Award | +227,000 | – | – | 577,000 |
| Edward B. Berg SVP, General Counsel | Mar 16, 2026 | Award | +115,000 | – | – | 799,858 |
| Steven Lo President, Chief Exec Officer, Director | Mar 16, 2026 | Award | +846,500 | – | – | 2,634,059 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 16, 2026 | Award | +200,000 | – | – | 931,225 |
| Edward B. Berg SVP, General Counsel | Feb 2, 2026 | Tax withholding | −9,265 | $0.61 | $5.65K | 684,858 |
| James F. Cummings Chief Medical Officer | Feb 2, 2026 | Tax withholding | −7,965 | $0.61 | $4.86K | 737,792 |
| Sean Tucker SVP, Chief Scientific Officer | Feb 2, 2026 | Tax withholding | −9,265 | $0.61 | $5.65K | 731,225 |
| Steven Lo President, Chief Exec Officer, Director | Dec 4, 2025 | Award | +151,351 | – | – | 1,841,712 |
| Steven Lo President, Chief Exec Officer, Director | Dec 4, 2025 | Tax withholding | −54,153 | $0.37 | $20.04K | 1,787,559 |
| W. Mark Watson Director | Nov 17, 2025 | Buy | +5,000 | $0.41 | $2.05K | 124,125 |
| W. Mark Watson Director | Nov 17, 2025 | Buy | +15,000 | $0.41 | $6.15K | 119,125 |
| Elaine J. Heron Director | Nov 17, 2025 | Buy | +16,783 | $0.41 | $6.88K | 96,566 |
| Elaine J. Heron Director | Nov 17, 2025 | Buy | +23,217 | $0.39 | $9.05K | 79,783 |
| Kevin Finney Director | Aug 15, 2025 | Buy | +50,000 | $0.37 | $18.50K | 204,771 |
| Kevin Finney Director | Aug 15, 2025 | Buy | +50,000 | $0.35 | $17.50K | 154,771 |
| Kevin Finney Director | Jul 30, 2025 | Buy | +25,874 | $0.38 | $9.83K | 104,771 |
| W. Mark Watson Director | Jul 29, 2025 | Buy | +10,000 | $0.41 | $4.10K | 104,125 |
| Kevin Finney Director | Jul 28, 2025 | Buy | +20,000 | $0.40 | $8.00K | 78,897 |
| Kevin Finney Director | Jul 25, 2025 | Buy | +20,000 | $0.39 | $7.80K | 58,897 |
| Kevin Finney Director | Jul 17, 2025 | Buy | +794 | $0.38 | $302 | 38,897 |
| Kevin Finney Director | Jun 13, 2025 | Award | +6,103 | – | – | 38,103 |
| W. Mark Watson Director | Jun 13, 2025 | Award | +16,000 | – | – | 94,125 |
| Michael J. Finney Director | Jun 13, 2025 | Award | +16,000 | – | – | 702,840 |
| David E. Wheadon Director | Jun 13, 2025 | Award | +16,000 | – | – | 46,750 |
| Elaine J. Heron Director | Jun 13, 2025 | Award | +16,000 | – | – | 56,566 |
| Jeroen Nicolaas Grasman Chief Financial Officer | May 19, 2025 | Award | +350,000 | – | – | 350,000 |
| Steven Lo President, Chief Exec Officer, Director | May 19, 2025 | Buy | +100,000 | $0.49 | $49.00K | 100,000 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 28, 2025 | Tax withholding | −3,913 | $0.42 | $1.64K | 740,490 |
| James F. Cummings Chief Medical Officer | Mar 28, 2025 | Tax withholding | −3,292 | $0.42 | $1.38K | 745,757 |
| Phillip E. Lee Chief Financial Officer | Mar 24, 2025 | Award | +406,000 | – | – | 631,619 |
| Edward B. Berg SVP, General Counsel | Mar 24, 2025 | Award | +406,000 | – | – | 694,123 |
| Steven Lo President, Chief Exec Officer, Director | Mar 24, 2025 | Award | +1,405,000 | – | – | 1,632,638 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 24, 2025 | Award | +406,000 | – | – | 744,403 |
| James F. Cummings Chief Medical Officer | Mar 24, 2025 | Award | +406,000 | – | – | 749,049 |
| Phillip E. Lee Chief Financial Officer | Mar 18, 2025 | Tax withholding | −8,050 | $0.57 | $4.59K | 225,619 |
| Edward B. Berg SVP, General Counsel | Mar 18, 2025 | Tax withholding | −8,050 | $0.57 | $4.59K | 288,123 |
| James F. Cummings Chief Medical Officer | Mar 18, 2025 | Tax withholding | −6,772 | $0.57 | $3.86K | 343,049 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 18, 2025 | Tax withholding | −8,050 | $0.57 | $4.59K | 338,403 |
| Steven Lo President, Chief Exec Officer, Director | Mar 18, 2025 | Tax withholding | −22,362 | $0.57 | $12.75K | 227,638 |
| James F. Cummings Chief Medical Officer | Feb 2, 2025 | Tax withholding | −7,964 | $0.68 | $5.42K | 318,837 |
| Edward B. Berg SVP, General Counsel | Feb 2, 2025 | Tax withholding | −9,242 | $0.68 | $6.28K | 261,464 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Joseph Finney Michael Former Director | Dec 8, 2025 | 40,000 | $14.40K | Dec 8, 2025 | Private Acquisition from Issuer/Affiliate |
| Phillip E. (VXRT) Lee Former Executive Officer | May 27, 2025 | 81,364 | $37.43K | May 27, 2025 | Deferred stock award |